PAFAH1B2抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P10062(PAFAH1B2 Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

**Background of PAFAH1B2 Antibody**

PAFAH1B2 (Platelet-Activating Factor Acetylhydrolase IB Subunit Beta 2) is a subunit of the intracellular PAFAH enzyme complex, which hydrolyzes platelet-activating factor (PAF) and related phospholipids. This enzyme complex comprises two catalytic subunits (PAFAH1B2 and PAFAH1B3) and a regulatory subunit (PAFAH1B1/LIS1). PAFAH1B2 plays a role in lipid metabolism, inflammation regulation, and cell signaling. It is structurally related to PAFAH1B1. a gene linked to neuronal migration disorders like lissencephaly, though PAFAH1B2’s specific functions remain less characterized.

PAFAH1B2 antibodies are tools used to study the protein’s expression, localization, and interaction partners. Research indicates PAFAH1B2 is upregulated in certain cancers (e.g., breast, lung, and liver cancers), where it may promote tumor progression, metastasis, and therapy resistance by modulating pathways like Wnt/β-catenin or PI3K/AKT. Its overexpression has also been associated with poor prognosis.

Antibodies targeting PAFAH1B2 enable detection via techniques like Western blotting, immunohistochemistry, and ELISA. They are critical for investigating its biological roles and clinical relevance. Validated antibodies should demonstrate specificity through controls like siRNA knockdown or recombinant protein blocking. Challenges include distinguishing PAFAH1B2 from homologous subunits and clarifying its precise mechanisms in disease contexts. Current studies focus on its potential as a therapeutic target or biomarker, though further research is needed to unravel its multifaceted roles in physiology and pathology.